Profiting from innovation through cross-border market co-creation and co-opetition: the case of global pharmaceuticals

Christos Pitelis, Panos Desyllas, Andreas Panagopoulos

Research output: Contribution to journalArticle

Abstract

We study the impact of the new intellectual property (IP) regime, as shaped by international agreements such as the Trade-Related-Aspects-of-IP-Rights (TRIPS), on the competitive positions of emerging country firms and advanced country multinational enterprises (AMNEs). Drawing on ideas from the IP, international business, and strategic management literatures, we formalize the market co-creation perspective and extend it to the emerging country - AMNE context. Using the pharmaceutical industry as our focus, we show that market co-creation-based co-opetition is preferable to both emerging and advanced country firms when the former can leverage their firm- and country-specific advantages and complementary assets to co-create new market space, even as they compete for value capture. We further show that co-opetition is fostered when the bargaining power of the AMNE (afforded through trade agreements) is counterbalanced by actions of emerging country firms and a robust IP law interpretation and enforcement by the host country’s courts.
LanguageEnglish
Article number12138
JournalEuropean Management Review
Early online date18 Sep 2017
DOIs
StatusPublished - 2017

Fingerprint

Coopetition
Pharmaceuticals
Co-creation
Cross-border
Innovation
Emerging countries
Multinational enterprises
Intellectual property
Trade agreements
Intellectual property law
Leverage
Pharmaceutical industry
Value capture
Bargaining power
Complementary assets
Intellectual property rights
International business
International agreements
Strategic management
Business management

Cite this

@article{3628f6f07a9f4ec5a62e212ac0139961,
title = "Profiting from innovation through cross-border market co-creation and co-opetition: the case of global pharmaceuticals",
abstract = "We study the impact of the new intellectual property (IP) regime, as shaped by international agreements such as the Trade-Related-Aspects-of-IP-Rights (TRIPS), on the competitive positions of emerging country firms and advanced country multinational enterprises (AMNEs). Drawing on ideas from the IP, international business, and strategic management literatures, we formalize the market co-creation perspective and extend it to the emerging country - AMNE context. Using the pharmaceutical industry as our focus, we show that market co-creation-based co-opetition is preferable to both emerging and advanced country firms when the former can leverage their firm- and country-specific advantages and complementary assets to co-create new market space, even as they compete for value capture. We further show that co-opetition is fostered when the bargaining power of the AMNE (afforded through trade agreements) is counterbalanced by actions of emerging country firms and a robust IP law interpretation and enforcement by the host country’s courts.",
author = "Christos Pitelis and Panos Desyllas and Andreas Panagopoulos",
year = "2017",
doi = "10.1111/emre.12138",
language = "English",
journal = "European Management Review",
issn = "1740-4754",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Profiting from innovation through cross-border market co-creation and co-opetition: the case of global pharmaceuticals

AU - Pitelis, Christos

AU - Desyllas, Panos

AU - Panagopoulos, Andreas

PY - 2017

Y1 - 2017

N2 - We study the impact of the new intellectual property (IP) regime, as shaped by international agreements such as the Trade-Related-Aspects-of-IP-Rights (TRIPS), on the competitive positions of emerging country firms and advanced country multinational enterprises (AMNEs). Drawing on ideas from the IP, international business, and strategic management literatures, we formalize the market co-creation perspective and extend it to the emerging country - AMNE context. Using the pharmaceutical industry as our focus, we show that market co-creation-based co-opetition is preferable to both emerging and advanced country firms when the former can leverage their firm- and country-specific advantages and complementary assets to co-create new market space, even as they compete for value capture. We further show that co-opetition is fostered when the bargaining power of the AMNE (afforded through trade agreements) is counterbalanced by actions of emerging country firms and a robust IP law interpretation and enforcement by the host country’s courts.

AB - We study the impact of the new intellectual property (IP) regime, as shaped by international agreements such as the Trade-Related-Aspects-of-IP-Rights (TRIPS), on the competitive positions of emerging country firms and advanced country multinational enterprises (AMNEs). Drawing on ideas from the IP, international business, and strategic management literatures, we formalize the market co-creation perspective and extend it to the emerging country - AMNE context. Using the pharmaceutical industry as our focus, we show that market co-creation-based co-opetition is preferable to both emerging and advanced country firms when the former can leverage their firm- and country-specific advantages and complementary assets to co-create new market space, even as they compete for value capture. We further show that co-opetition is fostered when the bargaining power of the AMNE (afforded through trade agreements) is counterbalanced by actions of emerging country firms and a robust IP law interpretation and enforcement by the host country’s courts.

U2 - 10.1111/emre.12138

DO - 10.1111/emre.12138

M3 - Article

JO - European Management Review

T2 - European Management Review

JF - European Management Review

SN - 1740-4754

M1 - 12138

ER -